Mark Graham shares that the company plans to explore nipocalimab's potential in targeting disease-driving pathways in SLE.
Strong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth ...
As of Monday, July 20, Viridian Therapeutics, Inc.’s VRDN share price has surged by 5.05%, which has investors questioning if ...
This important study provides a mechanistic view of how antibody affinity maturation can reshape encounter-state landscapes and association pathways, with implications for understanding HIV antibody ...
Michelle Monaghan was just 25 when she was struck down by the rare neurological condition Guillain-Barré syndrome. She shares ...
Michelle Monaghan was just 25 when she was struck down by the rare neurological condition Guillain-Barré syndrome. She shares ...
Nadia Mulliner was suffering increasingly frequent falls, but after several misdiagnoses, a physio finally sent her in the ...
BACKGROUND: Metabolic adaptation and maladaptation are hallmarks of the failing heart and may be a target for therapeutic ...
Autoantibodies are central to the diagnosis, classification, and stratification of many autoimmune diseases, particularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results